$pfe

**Pfizer's (PFE) current stock analysis indicates a mixed market sentiment with potential for growth.** Here's a detailed analysis:

1. **Technical Indicators**:
- The 5-day moving average is $30.35, the 10-day moving average is $30.05, and the 50-day moving average is $28.65. This suggests a short-term uptrend but a longer-term downtrend.
- The Relative Strength Index (RSI) is at 77.63, which is considered overbought territory and may indicate a potential pullback.
- The Moving Average Convergence Divergence (MACD) is at 0.22, showing a positive trend momentum.
- The Bollinger Bands show a width of 29.12, indicating a high volatility level.

|Ticker|Name|50-Day Moving Average|5-Day Moving Average|10-Day Moving Average|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|PFE.N|Pfizer|28.6500|30.3450|30.0535|20240730|PFE|169|

2. **Fundamental Analysis**:
- Pfizer reported a Net Income of $47 million and a Diluted EPS of $0.01 for the quarter ending June 30, 2024.
- The Net Income year-on-year growth rate is -97.99%, the Total Revenue year-on-year growth rate is 2.12%, and the Diluted EPS quarter-over-quarter growth rate is -98.18%.
- The company has a negative Net Income Growth Rate, which is a concern, but a positive Revenue Growth Rate.

|Ticker|Name|Total Revenue|Net Income|Diluted EPS|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|PFE.N|Pfizer|1.3283E10|4.7E7|0.01|2024 Q2|PFE|169|

|Ticker|Name|Net Income year-on-year growth rate|Total Revenue year-on-year growth rate|Diluted EPS QoQ growth rate|Date|code|market_code|
|---|---|---|---|---|---|---|---|
|PFE.N|Pfizer|-97.98973481608212|2.121934343046052|-98.18181818181819|20240630|PFE|169|

3. **Market Sentiment and Analysts' Views**:
- The consensus rating is a "Buy" with an average price target of $40.
- There has been a decrease in short interest, which could indicate a more bullish sentiment.
- Analysts have set a 52-week high price target of $45, suggesting potential upside.

4. **Upcoming Earnings and Guidance**:
- Pfizer is set to release its earnings data before the market opens on July 30th, with analysts expecting earnings of $0.45 per share for the quarter.
- The company has set its FY 2024 guidance at 2.150-2.350 EPS and its FY24 guidance at $2.15-2.35 EPS.
5. **Whale Activity and Options Trading**:
- Significant investors are aiming for a price territory stretching from $29.0 to $80.0 for Pfizer over the recent three months.
- The call put ratio indicates a bullish sentiment with 2.3 calls to 1 put into quarter results.

In conclusion, while Pfizer's technical indicators show a mixed picture, the positive analyst ratings and the recent earnings beat suggest potential for growth. However, the significant decrease in net income and the high volatility levels indicate risks. Investors should monitor the upcoming earnings release and consider the mixed fundamental and technical signals before making investment decisions.